Pharma

Pharmalot

Lawmakers press Gilead for pricing info on the Truvada HIV prevention pill

By Ed Silverman

Pharmalot

Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on

By Ed Silverman

Pharmalot

The AbbVie and Allergan deal: ‘Two turkeys don’t make an eagle’

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie will buy Allergan for $63 billion; Trump administration eyes candidates to run FDA

By Ed Silverman

Business

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

By Adam Feuerstein and Matthew Herper

Special Report

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

By Sharon Begley

Pharmalot

After FDA approval, drug makers often commit to follow-up studies. Few are new, a review finds

By Ed Silverman

Business

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Bristol pushes back Celgene deal; FDA approves another ‘female Viagra’

By Ed Silverman

Politics

VA declines broad coverage for new J&J depression drug touted by Trump

By Lev Facher and Ed Silverman

Pharmalot

ICER says pricing for Novartis MS drug ‘far out of line,’ but more groups push back

By Ed Silverman

Pharma

WHO rescinds opioid guidelines following criticism by two U.S. lawmakers

By Priyanka Dayal McCluskey — Boston Globe

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Merck CEO predicts challenges to Trump plan; progressives’ faux pricing hearing

By Ed Silverman

Biotech

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

By Adam Feuerstein

Pharma

FDA, accused of being too lax in approval of opioids, outlines new criteria for future approvals

By Andrew Joseph

Business

Drug-pricing watchdog group is ‘mouse that roared’

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Amazon wants to sell drugs directly through PillPack; Merck hunts for its next CEO

By Ed Silverman

Health Tech

Webinar: Progress and pitfalls in the AI-aided search for novel drugs

By Casey Ross and Kate Sheridan

Pharmalot

Do biologics really need 12 years of market exclusivity?

By Ed Silverman

Pharmalot

Pharmalittle: Azar battles White House officials; Merck seeks to expand beyond Keytruda

By Ed Silverman

Pharmalot

One-quarter of people with diabetes in the U.S. are rationing their insulin

By Ed Silverman

Pharmalot

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

By Ed Silverman

Pharmalot

With eyes on Gilead, lawmakers want details on how HHS reviews possible patent infringement

By Ed Silverman

Pharmalot

New proposal looks to involve every local U.S. government in opioid settlements

By Ed Silverman

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

Scott Gottlieb walks through the revolving door to the Pfizer board

Doctors Without Borders accuses Gilead Sciences of breaking a pledge for an HIV-related drug

Pharmalittle: Judges keep pharma secrets under wraps; Senate committees push drug pricing bills

Lawmakers press Gilead for pricing info on the Truvada HIV prevention pill

Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on

The AbbVie and Allergan deal: ‘Two turkeys don’t make an eagle’

Pharmalittle: AbbVie will buy Allergan for $63 billion; Trump administration eyes candidates to run FDA

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

After FDA approval, drug makers often commit to follow-up studies. Few are new, a review finds

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

Pharmalittle: Bristol pushes back Celgene deal; FDA approves another ‘female Viagra’

VA declines broad coverage for new J&J depression drug touted by Trump

ICER says pricing for Novartis MS drug ‘far out of line,’ but more groups push back

WHO rescinds opioid guidelines following criticism by two U.S. lawmakers

Up and down the ladder: The latest comings and goings

Pharmalittle: Merck CEO predicts challenges to Trump plan; progressives’ faux pricing hearing

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

FDA, accused of being too lax in approval of opioids, outlines new criteria for future approvals

Drug-pricing watchdog group is ‘mouse that roared’

Pharmalittle: Amazon wants to sell drugs directly through PillPack; Merck hunts for its next CEO

Webinar: Progress and pitfalls in the AI-aided search for novel drugs

Do biologics really need 12 years of market exclusivity?

Pharmalittle: Azar battles White House officials; Merck seeks to expand beyond Keytruda

One-quarter of people with diabetes in the U.S. are rationing their insulin

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

With eyes on Gilead, lawmakers want details on how HHS reviews possible patent infringement

New proposal looks to involve every local U.S. government in opioid settlements

Pharma

Sign up for our Daily Recap newsletter